Purpose: Despite earlier detection and stage migration, seminal vesicle invasion is still reported in the prostate specific antigen era and remains a poor prognostic indicator. We investigated outcomes in men with pT3b disease in the contemporary era.
from greater than 10%, but persist at approximately 6% of all RP specimens. 3 In-depth studies of pathological specimens have distinguished certain types of SVI, with lesser degrees having more a favorable prognosis. 4, 5 In the PSA era, SVI is most commonly via extraprostatic extension into the soft tissues adjacent to the prostate and SVs, and subsequently into the wall of the SVs. 4 Nevertheless, SVI is believed to be associated with occult micrometastatic disease, earlier biochemical recurrence and eventual disease progression. 6 The largest previous analysis of SVI included approximately 300 men and demonstrated a biochemical recurrence rate of greater than 60%. 7 A second analysis of 220 men similarly demonstrated a high rate of recurrence (54%) and no benefit to adjuvant or salvage therapy. 3 Using a larger, comprehensive database from our institution, we investigated outcomes in men with pT3b disease treated predominantly without ART in the contemporary era.
MATERIALS AND METHODS
The institutional review board approved, Johns Hopkins University RP database (1982 to present) was queried for men with pT3b disease. Of approximately 18,505 men who underwent RP 989 had SVI (pT3b disease). All patients at our institution undergo bilateral pelvic LN dissection. All RP specimens were processed. The SVI diagnosis was confirmed under standard protocol with SVI defined as tumor invading the muscular wall of the SV, which can occur by several mechanisms, of which the most common is extraprostatic extension at the base of the prostate, direct tracking along the ejaculatory duct complex, or via isolated, noncontiguous SV deposits. 4,8 -10 Of note, the route of invasion was not consistently documented and not considered in analysis. The cohort was grouped into 3 time based cohorts, including the prePSA (1982 to 1992), early PSA (1993 to 2000) and contemporary PSA (2001 to 2010) eras. The split between the early and contemporary PSA eras was based on the penetrance of PSA screening and incorporation of the Partin tables into clinical practice at our institution. 11, 12 A total of 257 men underwent RP before 1993 and 732 were identified in the PSA era, including 283 in the early and 447 in the contemporary eras, respectively. Appropriate comparative tests (the t and chisquare tests, and ANOVA) were used to determine differences in preoperative and postoperative characteristics among the eras.
Men with prostate cancer involving pelvic LNs were excluded from further survival analysis. A total of 242 men with LN invasion (N1) were excluded, yielding 155, 217 and 375 evaluable in each era, respectively. The Kaplan-Meier method was used to determine BFS, MFS and CSS among all 3 time cohorts. Men with pT3bN0 disease in the PSA era only were evaluated for predictors of BFS, MFS and CSS using univariate and multivariate proportional hazard models. Variables included preoperative PSA (0 to less than 10, 10 to less than] 20, and 20 or greater), clinical stage (cT2a or less, cT2b, and cT2c or greater), pathological Gleason sum (2-6, 7, and 8 -10) and positive SMs. Significant predictors of BFS, MFS and CSS on univariate analysis were included in the multivariate analysis.
RESULTS
A total of 989 men were identified with SVI (pT3b). The SVI rate was 12.7%, 5.7% and 3.9% in the prePSA, and early and contemporary PSA eras, respectively (p Ͻ0.001). In men with pT3bN0 disease, the 10-year BFS rate was 25.8%, 28.6% and 19.7% in the prePSA, and the early and contemporary PSA eras, respectively (p ϭ 0.8). The MFS rate was 62.9%, 71.9% and 75.7% (p ϭ 0.3), and the CSS rate was 79.9%, 79.6% and 83.9%, respectively (p ϭ 0.6, fig. 1 ). Table 2 lists the characteristics of the 592 patients with a median age of 59 ears (range 41 to 73) who had pT3bN0 disease and median PSA 7.7 ng/ml (range 0.1 to 84.1). Notably 202 men (34.2%) had positive SMs. In pT3bN0 cases in the PSA era, preoperative PSA (0 to less than 10, 10 to less than 20, and 20 or greater ng/ml), clinical stage (cT2a or less, cT2b, and cT2c or greater), pathological Gleason sum (2 to 6, 7, and 8 to 10) and positive SMs were significant predictors of BFS, MFS and CSS on univariate analysis, and were included in the final multivariate model. Multivariate analysis revealed that clinical stage cT2c or greater (HR 1.65, 95% CI 1.08 -2.51, p ϭ 0.02), pathological Gleason 7 (HR 14.4, 95% CI 6.9 -29.9, p Ͻ0.001), fig. 4 ).
In the contemporary PSA era, 30 men with pT3bN0 (5.1%) received ART, including 19 with positive SMs. A total of 141 men (41.1%) received adjuvant or salvage radiation (73 or 21.5%), hormone therapy (96 or 28.2%) and/or chemotherapy (29 or 8.9%). When the 144 patients who received adjuvant or salvage therapy were excluded, multivariate anal-ysis including the same variables as before indicated that pathological Gleason sum 8 -10 (HR 4.7, 95% CI 1.6 -13.6, p ϭ 0.004) and positive SMs (HR 2.5, 95% CI 1.4 -4.3, p ϭ 0.001) were predictors of BFS. In general, patients receive salvage therapy upon evidence of metastatic disease at our institution. Therefore, meaningful conclusions could not be drawn from analyses of MFS and CSS when treated patients were excluded.
DISCUSSION
By detecting prostate cancers at an earlier, more curable stage and allowing urologists to better select patients for RP through predictive nomograms such as the Partin tables, PSA changed the treatment and outcomes in men with prostate cancer. Consequently, fewer men have advanced grade 14 or stage 15 at RP. Specifically, prior studies have demonstrated and this study corroborates a decrease in the SVI rate in men who undergo RP. While the rate of SVI (pT3bN0) has more than halved from 7.%7 to 3.6%, SVI remains a strong predictor of biochemical recurrence and cancer specific mortality. 7, 16 In fact, despite improved detection of prostate cancer through PSA screening, the rates of biochemical recurrence, MFS and CSS in men with pT3b disease have remained remarkably stable from the prePSA to the contemporary eras. This finding is perplexing since preoperative characteristics, such as clinical stage and PSA, the node positive disease rate and positive SM status, appeared to improve as the era of surgery progressed. However, Gleason sum at biopsy and in the pathological specimen may explain the discrepancy between improved screening and earlier detection without an apparent survival advantage. Almost 20% of the men in the contemporary PSA era with pT3b disease had biopsy Gleason sum 8 -10, and almost 40% had Gleason 8 -10 at RP analysis. These values approximate the rates of advanced grade disease in the prePSA era. While this represents the experience at a single, large tertiary referral center and may be biased by referral patterns, we postulate that the improvements in clinical stage, PSA and pathological stage prompted by PSA screening (as manifested by the decreasing rate of pT3b disease) are offset by the relatively stable proportion of men with high risk Gleason sum in the pT3b population.
Eggener et al reported similar improvements in clinical stage, preoperative PSA and positive SMs between the prePSA and PSA eras, and a concomitant increase in pathological Gleason grade. 3 However, they noted improvements in BFS and CSS in the contemporary PSA era at 4 and 7 years that were not seen in our analysis. The improvement in BFS and CSS in their study was only seen on uni- an important predictor of outcome on multivariate analysis, most likely since our approach focused more directly on the PSA era, so that PSA levels were truncated by improved screening and detection. An earlier analysis from our institution confirmed the importance of Gleason sum and SM status in predicting BFS. 18 Importantly, high risk clinical stage and Gleason sum were predictors of MFS and CSS in this cohort, which is valuable information when counseling patients found to have SVI at RP.
The earlier study from our institution also concluded that SVI is not uniformly associated with a poor prognosis. While most men experience biochemical recurrence, patients can be counseled that most will survive many years despite prostate cancer growth beyond the gland. In fact, we observed favorable MFS and CSS rates of 70% and 80%, respectively, at 10 years in men with pT3bN0 disease. Eggener et al similarly found that 80% to 93% of men with SVI were alive at 7 years. 3 In the Southwest Oncology Group 8794 study of a cohort of men with pT3N0M0, the MFS and CSS rates at 10 years were 71% and 74% in the groups receiving ART, and 61% and 66%, respectively, in the groups not receiving ART. 19 By comparison, only 5% and 40% of men in our analysis went on to receive adjuvant radiation and salvage treatments, respectively, in the form of radiation, hormone therapy or chemotherapy. In general, men at our institution receive salvage hormonal therapy only when demonstrable metastatic lesions are identified, not biochemical recurrence. Therefore, the low secondary treatment rate suggests that men with SVI can expect favorable, longterm CSS with relatively low rates of adjuvant and salvage therapy.
Despite the known risk of recurrence, there is no consensus regarding the role of adjuvant and salvage radiation therapy in these men. Traditionally, men with SVI respond poorly to ART. 20, 21 However, the Southwest Oncology Group 8794 trial demonstrated metastasis-free and overall survival benefits in all men with pT3 disease treated with immediate adjuvant radiation therapy. 19 Conversely, the European Organization for Research and Treatment of Cancer 22911 22 and the phase III ARO96-09/AUO09-95
23 trials failed to demonstrate a survival benefit in men with pT3b disease treated with ART. Nonetheless, several groups have noted an improvement in the biochemical recurrence rate, in the range of 10% to 38%, in men with SVI treated with salvage radiation therapy. 24 -28 Due to restraints in the timing and duration of treatments, conclusions regarding ART and additional treatments from our analysis should be viewed with prudence. In addition to the lack of time dependent salvage treatment information, there are a number of other important limitations inherent to the retrospective nature of this study. Importantly, preoperative selection bias, modifications in surgical technique and changes in prostate cancer grading over the eras certainly influenced the capture and interpretation of these data. Importantly, since minimally invasive approaches to RP are associated with higher SM rates, 29, 30 the use of laparoscopic and robot assisted surgery in the contemporary PSA era could have influenced outcomes in these patients. A significant omission from this analysis is the route of SVI. While some studies show that the SVI route carries important information regarding biochemical recurrence, it is currently believed that the SVI route is not prognostic in patients lacking LN metastasis. 9, 10, 18 Therefore, it was justifiably omitted from our analysis. It is also established that the finding of SVI can vary among institutions and pathologists. 17 Analysis of all RP specimens at our institution is completed by an experience genitourinary pathologist in a uniform manner. 
